热门资讯> 正文

NeuSense Therapeutics GAAP每股收益为-0.54美元

2025-04-08 15:45

Neurosense Therapeutics Ltd.(NRSN) 0

NeuroSense Therapeutics press release (NASDAQ:NRSN): FY GAAP EPS of -$0.54.
As of December 31, 2024, NeuroSense had cash of approximately $3.4 million.

More on NeuroSense Therapeutics

Seeking Alpha’s Quant Rating on NeuroSense Therapeutics
Historical earnings data for NeuroSense Therapeutics
Financial information for NeuroSense Therapeutics

推荐文章

风险及免责提示：以上内容仅代表作者的个人立场和观点，不代表华盛的任何立场，华盛亦无法证实上述内容的真实性、准确性和原创性。投资者在做出任何投资决定前，应结合自身情况，考虑投资产品的风险。必要时，请咨询专业投资顾问的意见。华盛不提供任何投资建议，对此亦不做任何承诺和保证。